Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.48 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672245 | 0.89 | CA12 (0.61) | L3MBTL1GLACA12CA1CA2 | |
| SCHEMBL27051701 | 0.86 | KMT2A (0.47) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL2447016 | 0.85 | L3MBTL1 (0.55) | L3MBTL1GLACA12CA1CA2 | |
| SCHEMBL10339837 | 0.85 | TP53 (0.50) | TDP1TSHR | |
| SCHEMBL23748674 | 0.83 | PPARA (0.50) | TDP1MAPTLMNAMEN1KMT2A | |
| SCHEMBL31643476 | 0.83 | PTPN1 (0.55) | L3MBTL1CA12CA1CA2CA7 | |
| SCHEMBL9502979 | 0.82 | MEN1 (0.52) | TDP1ALDH1A1HPGDMAPTLMNA | |
| SCHEMBL9504277 | 0.82 | MEN1 (0.52) | TDP1ALDH1A1HPGDMAPTLMNA | |
| SCHEMBL22408082 | 0.82 | L3MBTL1 (0.51) | L3MBTL1GLACA12CA1CA2 | |
| SCHEMBL5464526 | 0.82 | CA12 (0.55) | L3MBTL1GLACA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4276193-A | MAGNESIUM DIHALIDE CARRIER, CATALYST COMPRISING AN ELECTRON DONOR, TITANIUM TETRACHLORIDE REDUCED WITH AN ORGANOALUMINUM HALIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-06-30 | — | — | US | claimed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| CN-118451078-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-18 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240027903-A1 | Resist Material And Patterning Process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-25 | — | — | US | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2023061440-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-04-20 | — | — | WO | disclosed |
| EP-4157888-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2023-02-23 | — | — | US | disclosed |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-06-09 | — | — | US | disclosed |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-02-08 | — | — | US | disclosed |
| WO-2021239117-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI) , INC. (CN) | 2021-12-02 | — | — | WO | disclosed |
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-09-17 | — | — | US | disclosed |
| EP-0008764-B1 | PROCESS FOR THE PREPARATION OF A CATALYST ON A SOLID CARRIER AND ITS USE IN THE POLYMERISATION OF PROPYLENE | BAYER AG (DE) | 1982-09-22 | — | — | EP | disclosed |
| US-4276193-A | MAGNESIUM DIHALIDE CARRIER, CATALYST COMPRISING AN ELECTRON DONOR, TITANIUM TETRACHLORIDE REDUCED WITH AN ORGANOALUMINUM HALIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-06-30 | — | — | US | disclosed |
| EP-0008764-A2 | Process for the preparation of a catalyst on a solid carrier and its use in the polymerisation of propylene | BAYER AG (DE) | 1980-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289507-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | L3MBTL1 4704/4885GLA 3970/4885CA12 4750/4885 |
| US-20220175775-A1 | N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | L3MBTL1 4704/4885GLA 3970/4885CA12 4750/4885 |
| US-12011444-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | L3MBTL1 4704/4885GLA 3970/4885CA12 4750/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | L3MBTL1 707/4885GLA 3308/4885CA12 4415/4885 |
| US-20240027903-A1 | Resist Material And Patterning Process | LBR, HNRNPU, EWSR1 | L3MBTL1 774/4885GLA 3643/4885CA12 2389/4885 |
| US-11241431-B2 | N-substituted indole derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | L3MBTL1 4704/4885GLA 3970/4885CA12 4750/4885 |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | L3MBTL1 1176/4885GLA 2922/4885CA12 4484/4885 |
| US-20230057177-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | L3MBTL1 707/4885GLA 3308/4885CA12 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.